Humacyte - HUMA Company Short-Term Debt

Graphic logo of Humacyte, Inc. (HUMA)

Humacyte, Inc. (HUMA) creates unique artificial vessels, ensuring stable demand across specialized medical centers. The business relies on strict bioreactor monitoring and eco-friendly waste disposal. This price chart illustrating trading dynamics reflects the 0.00 indicator, while compliance with environmental standards will become a key factor for the company's sustainable development in the future.

Humacyte Inc (HUMA) Company Short-Term Indebtedness: for the period 07/04/2022 - 10/28/2026

HUMA (Humacyte Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Humacyte|HUMA - Fair Value Consensus
- market capitalization data:
Market Value Humacyte, Inc.|HUMA - Total Enterprise Value
- book capitalization data:
Book Value per Share Humacyte|HUMA - Accounting Capitalization|Market Cap to Net Assets Ratio humacyte.com|HUMA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Humacyte, Inc.|HUMA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Humacyte, Inc.|HUMA - Company Cumulative Indebtedness|Debts to Book Capitalization Humacyte, Inc.|HUMA - Long-Term Debt Volume|Company Short-Term Debt Humacyte
Analysis of all company metrics:Humacyte HUMA
Flagship merchandise of humacyte.com

To select high-quality assets, investors analyze liquidity through the lens of debt load. This metric measures obligations maturing within one year, determining current financial stability. For Humacyte, Inc. (HUMA), this reserve is critical in the event of Asian supply chain disruptions or clinical trial delays caused by sanctions. An optimal debt balance supports return on equity. The dynamics of total short-term debt reflect the company's ability to mitigate geopolitical risks.

Competitor analysis for Humacyte, Inc.

Company Short-Term Debt Natera (NTRA)|SERA: Company Short-Term Loans and Borrowings